Stockscreener 앱 받기
1.205
0.82%
-0.015
전일 마감가:
$1.22
열려 있는:
$1.21
하루 거래량:
208.68K
Relative Volume:
0.15
시가총액:
$31.55M
수익:
$1.79M
순이익/손실:
$-70.90M
주가수익비율:
-0.0775
EPS:
-15.54
순현금흐름:
$-34.95M
1주 성능:
-14.49%
1개월 성능:
-29.24%
6개월 성능:
-46.93%
1년 성능:
-69.83%
1일 변동 폭
$1.175
$1.24
1주일 범위
$1.15
$1.3699
52주 변동 폭
$1.15
$5.10
센티 바이오사이언시스 Stock (SNTI) Company Profile
명칭
Senti Biosciences Inc
전화
(650) 239-2030
주소
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
SNTI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Inc
|
1.20 | 32.07M | 1.79M | -70.90M | -34.95M | -15.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.60 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.10 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.57 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
851.74 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.77 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
센티 바이오사이언시스 Stock (SNTI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-14 | 개시 | H.C. Wainwright | Buy |
| 2025-06-06 | 개시 | Laidlaw | Buy |
| 2022-10-07 | 개시 | Morgan Stanley | Equal-Weight |
센티 바이오사이언시스 주식(SNTI)의 최신 뉴스
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Senti Biosciences Inc. (SNTI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Promising Biotech Stocks To Keep An Eye OnDecember 9th - MarketBeat
Senti Biosciences (NASDAQ:SNTI) Rating Increased to Sell at Wall Street Zen - Defense World
Promising Biotech Stocks To Keep An Eye On – December 9th - Defense World
Senti Bio Wins FDA RMAT Designation for SENTI-202 on 50% Response Rate in Leukemia Trial - geneonline.com
Senti Biosciences: Understanding the Market Moves - StocksToTrade
Chardan Raises Price Target on Senti Biosciences to $13 From $12, Keeps Buy Rating - marketscreener.com
Check Out Senti Biosciences Inc (SNTI)’s Trade Data Rather Than the Analysts’ Views - Setenews
Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation - Menafn
Senti Bio’s SENTI-202 shows promising results in AML clinical trial By Investing.com - Investing.com Australia
Biotech Stocks Today: FDA Shifts, ASH 2025 Winners and Market Close Recap (December 9, 2025) - ts2.tech
Unveiling Senti Biosciences: Shaping the Future of Cancer Therapy? - StocksToTrade
Senti Bio price target raised to $13 from $12 at Chardan - TipRanks
Why Is Gene Therapy Focused Senti Bio Stock Falling Today? - Benzinga
Lyft Stock Soars Following Strategic Euro Expansion Through FreeNow Acquisition - StocksToTrade
Senti Biosciences’ Strategic Moves Ripple Across Biotech Market - timothysykes.com
Senti Biosciences Secures FDA RMAT Designation For SENTI-202 - Nasdaq
Senti Biosciences Announces Positive Data From Ongoing SENTI-202 Trial, Stock Up - Nasdaq
Senti Announced Positive Phase 1 Data For SENTI-202 In Relapsed/ Refractory AML - Nasdaq
Senti Biosciences’ Surge: Buy or Wait? - timothysykes.com
Senti Biosciences Reports Promising Phase 1 Trial Results - TipRanks
Senti Bio’s SENTI-202 shows promising results in AML clinical trial - Investing.com
Senti Bio stock soars after positive cancer therapy trial results By Investing.com - Investing.com Canada
Senti Bio Announces Updated SENTI-202 Clinical Data from Ongoing Phase 1 Trial in Relapsed or Refractory Acute Myeloid Leukemia Patients, Demonstrating Deep, MRD Negative, Durable Complete Remissions and a Favorable Safety Profile - The Manila Times
Senti Biosciences, Inc. Announces Initial Clinical Data for SENTI-202 - TradingView — Track All Markets
Senti Bio Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for SENTI-202 in the Treatment of Adults with Relapsed or Refractory Acute Myeloid Leukemia - marketscreener.com
Is Senti Biosciences Inc a good long term investmentLong-Term Investment Plans & Small Investment Growth Plans - earlytimes.in
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Senti Biosciences, Inc. to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented At the American Society of Hematology Annual Meeting 2025 - marketscreener.com
Senti Biosciences, Inc. to Host Conference Call on Updated Clinical Results for SENTI-202 Prior to ASH Annual Meeting - Quiver Quantitative
Senti Bio (Nasdaq: SNTI) to host Dec. 9 webcast on updated SENTI-202 data from ASH 2025 - Stock Titan
How Senti Biosciences Inc. stock reacts to oil pricesJuly 2025 Price Swings & Capital Efficiency Focused Strategies - Newser
Senti Biosciences (SNTI) Stock Analysis Report | Financials & Insights - Benzinga
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 - ADVFN
Form 8-KCurrent report - ADVFN
Senti Biosciences, Inc. (NASDAQ:SNTI) Receives $8.75 Consensus PT from Analysts - Defense World
Leerink Partners Initiates Coverage on Senti Biosciences (NASDAQ:SNTI) - Defense World
SNTI Stock Skyrockets on Initial Data From Phase I Cancer Study - MSN
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating - Investing.com Australia
Leerink Partners Initiates Coverage of Senti Biosciences (SNTI) with Outperform Recommendation - Nasdaq
Leerink Partners initiates coverage on Senti Biosciences stock with Outperform rating By Investing.com - Investing.com South Africa
SNTI Stock Rating Update: Leerink Partners Initiates Coverage | - GuruFocus
Why Senti Biosciences Inc. stock is a must watch in 20252025 Breakouts & Breakdowns & Free Long-Term Investment Growth Plans - newser.com
Is Senti Biosciences Inc. stock vulnerable to regulatory risksJuly 2025 Closing Moves & Weekly High Return Forecasts - newser.com
Why Senti Biosciences Inc. stock could benefit from AI revolutionWeekly Gains Summary & Technical Entry and Exit Tips - newser.com
Is Senti Biosciences Inc. trending in predictive chart modelsQuarterly Market Summary & Expert Approved Momentum Ideas - newser.com
센티 바이오사이언시스 (SNTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.89%
0.73%
자본화:
|
볼륨(24시간):